Biotech Stocks Volume Gainers : Alert by Penny Stock Pick Report

ArQule, Inc. (NASDAQ:ARQL) added 4.32% to $6.04 after today it announced that the Company will present at the 17th Annual Future Leaders in the Biotech Industry conference on Thursday, April 8, 2010 at 3:00 p.m. eastern time.

Subscribe to daily free stock newsletter by visiting:  http://www.pennystockpickreport.com/

Keryx Biopharmaceuticals (NASDAQ:KERX) soared 20.07% and is trading at $3.29 after it  announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer. The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Today the stock also touched a new 52 week high at $3.56.  

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) zoomed 27.48% to $1.02 after today announced that its partner, Keryx Biopharmaceuticals (NASDAQ: KERX), was granted Fast Track designation by the U.S. Food and Drug Administration ("FDA") for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.  

ARCA biopharma, Inc. (NASDAQ:ABIO) gains 3.82% to $5.17. Over the last 52 weeks the stock has ranged from a low of $2.20 to a high of $13.45.

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) surged 7.33% to $2.49. Over the last 52 weeks the stock has ranged from a low of $0.30 to a high of $4.08.

MDRNA, Inc. (NASDAQ:MRNA) today announced a study effort with Pfizer (NYSE: PFE). The relationship will focus on the evaluation of MDRNA's proprietary di-alkylated amino acids (DiLA2) platform and UsiRNA constructs for RNA interference (RNAi). Additional details of the collaboration were not disclosed. The stock climbed 5.04% to $1.25.

Rexahn Pharmaceuticals, Inc. (AMEX:RNN) spurted 11.05% to $1.81 after it announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of Parkinson's disease (PD).

Repros Therapeutics Inc. (NASDAQ:RPRX) jumped 15.20% to $0.704 after it announced that the Company has requested a lift of the full clinical hold on its oral drug Proellex being developed for the treatment of uterine fibroids and endometriosis.  

VIVUS, Inc. (NASDAQ:VVUS) gains 2.44% to $9.03. . Over the last 52 weeks the stock has ranged from a low of $3.61 to a high of $12.88.

About http://www.pennystockpickreport.com/

Penny Stock Pick Report offers stock newsletter on OTC, PINKSHEETS ,OTCBB, AMEX, NASDAQ and NYSE stock exchange. Our subscribers receive daily up to date stock information on hot stocks ,most active movers, top gainers, penny stocks and much more. If you wish to feature your organization on our website then you can contact us at the email given below.